Mung Bean Extract for Health & Longevity
Evidence Review created on 10/08/2026 using AI4L + evidence-mcp / Sonnet 5.5
Also known as: Vigna radiata Extract, Mungbean Extract, Green Gram Extract, Moong Extract, Mung Bean Seed Coat Extract, Mung Bean Coat Extract
Motivation
Mung bean extract refers to concentrated preparations of Vigna radiata (green gram), a legume consumed for centuries across South and East Asia. The best-known supplement form comes from the seed coat, which is rich in plant antioxidants; other preparations isolate the bean’s protein or concentrate its sprouts.
Mung bean has a long record in traditional Chinese and Indian medicine. Laboratory work on a water-based seed-coat extract examined inflammatory responses in immune cells, and the extract is now sold as a supplement, in one product combined with a green tea compound. Human trials have so far studied the bean’s protein fraction, mainly for insulin handling and muscle strength.
This review examines what is known about mung bean extract in the context of health and longevity for adults who optimize their health actively: the type and quality of evidence behind each proposed benefit, documented risks, doses used in studies, interactions, and open questions. It keeps seed-coat extract separate from other mung bean preparations because the evidence base for each differs.
Benefits - Risks - Protocol - Conclusion
Recommended Reading
Expert and narrative-review overviews of mung bean extract and its proposed health effects.
-
The Mighty Mung Bean - William Gamonski
Life Extension Magazine overview of mung bean extract, covering effects on cholesterol oxidation, blood glucose, cancer cells and satiety. Cites animal, cell and human food studies; the publisher sells a mung bean extract product.
-
Mung Bean (Vigna radiata L.): Bioactive Polyphenols, Polysaccharides, Peptides, and Health Benefits - Hou et al., 2019
Narrative review of mung bean polyphenols (plant antioxidant compounds), polysaccharides (complex carbohydrates) and peptides (short protein fragments), listing reported effects on blood glucose, blood lipids (fats) and blood pressure. Human trial data are sparse.
No relevant content on mung bean extract was found from Rhonda Patrick (FoundMyFitness), Peter Attia, Andrew Huberman, Chris Kresser or Lifespan.io; site searches and web searches returned no page discussing mung bean extract in depth (a Kresser podcast mentions mung beans only briefly). Fewer than five sources qualified, so the list is not padded with marginally relevant content.
Grokipedia
AI-written encyclopedia article covering mung bean botany, nutrient content and bioactive compounds such as vitexin and isovitexin; its health claims rest mainly on animal studies.
Examine
No Examine article on mung bean extract exists.
ConsumerLab
No ConsumerLab article on mung bean extract exists.
Systematic Reviews
Systematic reviews and meta-analyses found on PubMed that cover mung bean as of October 8, 2026.
-
A review of the toxicological effects and allergenic potential of emerging alternative protein sources - Milana et al., 2025
Systematic literature review covering mung bean among ten alternative protein sources; addresses allergenic potential and antinutritional factors (nutrient-absorption blockers), not mung bean extract.
No systematic review or meta-analysis of the claimed benefits of mung bean extract was found, so only the risk side is represented.
Mechanism of Action
Mung bean extracts act through several proposed routes, established mainly in cells and animals.
Seed-coat flavonoids: The coat is rich in vitexin and isovitexin (flavonoids, antioxidant plant compounds). In Caenorhabditis elegans roundworms, a coat extract extended lifespan via mitochondrial function and calorie-restriction-like signaling (Tao et al., 2021), and in neurodegeneration models it acted through AMPK (AMP-activated protein kinase, a cellular energy sensor)-dependent autophagy (cellular recycling) (Chen et al., 2026). In macrophage (immune-cell) cultures, a water-based coat extract lowered release of HMGB1 (a protein that amplifies inflammation) and raised survival in mice with sepsis (a life-threatening reaction to infection), possibly through autophagic HMGB1 breakdown (Zhu et al., 2012).
Protein fraction: The main protein, 8S globulin (a seed protein), resembles the soy protein β-conglycinin and is proposed to suppress liver fat synthesis via SREBP-1 (a fat-synthesis regulator) and raise adiponectin (a fat-tissue hormone) (Kohno et al., 2018; authors from the manufacturer, Fuji Oil). In mice, weight effects depended on gut bacteria and bile acids (Nakatani et al., 2018). Mung bean protein inhibited ACE (angiotensin-converting enzyme, which raises blood pressure) in vitro (Muchimapura et al., 2024).
Competing view: Antioxidant action may be modest: mung bean showed the weakest antioxidant activity among four Vigna species (Sreerama et al., 2012), and a lipid-damage marker did not change in a human trial (Muchimapura et al., 2024).
Absorption and distribution: Intravenous isovitexin had a half-life near one hour in rats, concentrating in kidney, intestine and liver (Li et al., 2015); human absorption and metabolism are unreported.
Historical Context & Evolution
Mung bean (Vigna radiata) was domesticated in India, with archaeological evidence dating to about 1500 BC, and spread through Asia as a staple pulse; traditional use credited it with protection against heat stroke (Life Extension Magazine). In China it has served as food and herbal medicine against inflammatory conditions since the 1050s (Zhu et al., 2012).
The seed coat, removed when beans are peeled, became the extract’s focus when a New York research group reported that a water-based coat extract lowered release of an inflammation-amplifying protein in immune cells and improved survival in mice with sepsis (Zhu et al., 2012); the extract is now sold in a supplement paired with a green tea compound (Life Extension product page).
A separate line began with mung bean protein isolate, a starch-production by-product developed by a Japanese food manufacturer as a soy-protein alternative and tested in two human trials (Kohno et al., 2018). The U.S. Food and Drug Administration (FDA) closed a notice on the generally recognized as safe (GRAS, a food-safety designation) status of a different mung bean protein isolate, from another notifier, in 2017 with no questions (FDA GRAS Notice inventory entry for mung bean protein isolate, GRN 684). Roundworm lifespan experiments in 2021 added a longevity rationale (Tao et al., 2021). The evidence has not settled: no controlled human trial has tested the seed-coat extract.
Expected Benefits
High 🟩 🟩 🟩
No benefit reaches High: the human trials are small, tested mung bean protein rather than seed-coat extract, and no outcome has been replicated by an independent research group.
Medium 🟩 🟩
No benefit reaches Medium: every controlled human trial of a mung bean preparation tested protein or whole food instead of the seed-coat extract, which makes the evidence indirect, and the seed-coat extract itself has no human outcome data.
Low 🟩
Insulin Sensitivity & Triglycerides
Mung bean protein isolate, not seed-coat extract, was tested in an 8-week placebo-controlled trial by authors from its manufacturer, Fuji Oil (Kohno et al., 2018). Insulin and HOMA-IR (a calculated insulin-resistance index) fell in the isolate group, while fasting glucose did not change. The different form makes the evidence indirect.
Magnitude: In all participants (22 per group), the paper reports within-group changes for isolate and milk-protein (casein) placebo, not compared between groups: fasting insulin fell from 14.9 to 10.8 µU/mL with isolate and rose from 12.2 to 13.7 with placebo; HOMA-IR fell from 3.8 to 2.9 versus 2.8 to 3.3; triglycerides moved from 153 to 142 (a tendency only) versus 136 to 146 mg/dL. In the subgroup with HOMA-IR of 1.7 or higher (20 isolate, 16 placebo), net changes versus placebo, reported as significant, were -4.1 versus +1.8 µU/mL (insulin), -1.0 versus +0.6 (HOMA-IR) and -15 versus +10 mg/dL (triglycerides); no 95% confidence interval (CI, the range likely to contain the true value) is reported.
Muscle Strength (Protein Supplementation)
Mung bean protein (18 g/day) was given for 8 weeks to underactive vegetarian adults in a randomized trial against a control biscuit (Bartholomae et al., 2019). Lean mass did not differ between groups; the strength difference was borderline. Protein, not extract, was tested, so the evidence is indirect.
Magnitude: Average percent change in grip, knee flexor and knee extensor strength differed between groups (p = 0.05, the chance of a difference this large arising from random variation alone; borderline): +2.9% with mung bean protein (11 completers) versus -2.6% with control (14 completers); no 95% CI reported.
Artery Function (Flow-Mediated Dilation)
In a 6-week placebo-controlled trial, 27 healthy adults aged 45-60 consumed mung bean protein orally at 10 or 15 g/day; flow-mediated dilation (FMD, artery widening after a brief blood-flow block) rose versus placebo (Muchimapura et al., 2024). Groups were about nine people, and protein rather than extract was tested.
Magnitude: Both doses produced a larger percent change in brachial-artery diameter during FMD than placebo, described by the authors as significant; the paper gives no numeric values or 95% CI in its text (figure only), so the size is not available from the literature text.
Post-Meal Blood Glucose & Diabetic Control (Whole Mung Bean Foods)
Starch noodles had a glycemic index (a ranking of blood-sugar rise after consumption) of 28 (Lin et al., 2010); 11-90 across studies (Singh et al., 2021, a review). A crossover trial tested noodles in 10 women with type 2 diabetes (Komindr et al., 2001). Food evidence is indirect for extract.
Magnitude: Glycemic index 28 for mung bean starch noodles versus reference bread in ten healthy adults (no 95% CI reported); across reviewed studies, mung bean preparations ranged from 11 to 90 with glucose as the reference, depending on processing. In the 4-week crossover trial, HbA1 (a long-term blood-sugar marker) was better than baseline after all diets and best after the mung bean noodle diet, while integrated plasma glucose did not differ between diets; the abstract gives no numeric values or 95% CI.
Cancer Risk & Cancer-Cell Growth Inhibition
Whole-food mung bean pancake consumption was associated with lower stomach cancer risk in a Korean case-control study (213 patients versus 213 matched people without cancer) (Lee et al., 1995). Pancake, not extract, was studied, so the evidence is indirect; cell-based growth-slowing effects are listed (Hou et al., 2019, a review).
Magnitude: Mung bean pancake consumption was associated with decreased stomach cancer risk; the abstract reports no numeric risk estimate or 95% CI, and the design was observational.
Liver Enzymes (ALT) & Liver Protection
Mung bean protein isolate, not seed-coat extract, lowered ALT (alanine aminotransferase, a liver enzyme) in an 8-week placebo-controlled trial (Kohno et al., 2018). An ethanol extract limited alcohol-induced liver injury in mice (Liu et al., 2025). Human evidence is indirect.
Magnitude: In all participants (22 per group), ALT fell from 35.3 to 30.6 IU/L with isolate (within-group p < 0.05) and rose slightly with casein placebo, not compared between groups in that analysis. In the subgroup with HOMA-IR of 1.7 or higher (20 isolate, 16 placebo), net change versus placebo was -5.6 versus +4.6 IU/L (p < 0.01); no 95% CI reported.
Speculative 🟨
Lifespan Extension & Aging Markers
A vitexin- and isovitexin-rich coat extract lengthened roundworm lifespan (Tao et al., 2021), and mung bean protein raised antioxidant enzymes in aging mice (Zhang et al., 2022). No human aging outcomes exist.
Antioxidant Capacity & Oxidative Stress ⚠️ Conflicted
Seed extracts inhibited LDL (cholesterol-carrying particles) oxidation in vitro (Chung et al., 2011). A protein drink raised glutathione peroxidase (an antioxidant enzyme), not a lipid-damage marker (Muchimapura et al., 2024). Net reading: unconfirmed in people.
Gut Microbiota Modulation (Seed-Coat Extract)
Mung bean coat enriched Roseburia and Bifidobacterium in prediabetic mice (Hou et al., 2021), and coat extract shifted gut bacteria in high-fat-fed rats (Charoensiddhi et al., 2024). No human data exist.
Cholesterol Lowering ⚠️ Conflicted
Mung bean coat lowered total cholesterol in prediabetic mice (Hou et al., 2021); cholesterol did not change in the human isolate trial (Kohno et al., 2018). Net reading: unconfirmed in people.
Inflammation & Sepsis Protection
A seed-coat extract raised septic-mouse survival from 29.4% to 70% (Zhu et al., 2012); a protein drink lowered NF-κB, TNF-α and IL-6 (inflammatory signaling molecules) in 27 adults (Muchimapura et al., 2024). Markers are unvalidated.
Neuroprotection
A coat extract reduced Alzheimer’s- and Parkinson’s-related protein toxicity in roundworm and cell models through AMPK-dependent autophagy (Chen et al., 2026). No human cognitive data exist.
Blood Pressure Lowering
Mung bean protein drinks inhibited ACE in vitro (Muchimapura et al., 2024), and hypertension is listed among documented effects (Hou et al., 2019, a review). No trial has tested blood pressure with mung bean extract.
Adiponectin Increase (Protein Isolate)
Adiponectin (a fat-tissue hormone) rose more with mung bean protein isolate than with casein placebo in the 8-week trial (Kohno et al., 2018). Adiponectin is an unvalidated biomarker, and the isolate is not the extract.
Body Weight & Fat Mass ⚠️ Conflicted
Mung bean protein reduced weight gain in high-fat-fed mice (Nakatani et al., 2018), but human body-fat changes in the isolate trial were not significant (Kohno et al., 2018). Net reading: unconfirmed in people.
Benefit-Modifying Factors
- Genetic polymorphisms: No gene variants have been examined as modifiers of mung bean extract response; the human trials contain no genotype analyses.
- Baseline biomarkers: In the isolate trial, participants with HOMA-IR of 1.7 or higher (lower insulin sensitivity) were analyzed separately, and the authors reported larger benefits in that group (Kohno et al., 2018).
- Sex: The isolate and artery-function trials enrolled both sexes but reported no sex-stratified results, so sex-based differences in benefit are unknown (Kohno et al., 2018; Muchimapura et al., 2024).
- Pre-existing conditions: Trials enrolled healthy adults or adults with prediabetic-range fasting glucose, overweight or raised triglycerides (Kohno et al., 2018; Muchimapura et al., 2024); a 10-woman noodle crossover trial studied type 2 diabetes (Komindr et al., 2001); none studied kidney or liver disease.
- Age: Participants were 21-55 years (Kohno et al., 2018) and 45-60 years (Muchimapura et al., 2024); no trial reported older-adult subgroup results, including for the older end of the target range.
- Gut microbiota: In mice, mung bean protein effects depended on gut bacteria and were abolished in germ-free animals, so microbiome composition may modify response; this is untested in humans (Nakatani et al., 2018).
Potential Risks & Side Effects
High 🟥 🟥 🟥
No risk reaches High: no controlled trial has documented an adverse event from mung bean extract, and the documented harms come from case series and outbreak investigations of seedlings and sprouts.
Medium 🟥 🟥
No risk reaches Medium: the best-documented harms were observed with raw sprouts, seedlings or seeds rather than extract, which makes them indirect evidence.
Low 🟥
Allergic Reactions
Independent groups documented reactions to seedlings or seeds: IgE (allergy antibody) reactivity shared with birch pollen (Mittag et al., 2005; Guhsl et al., 2014) and seed-protein binding (Misra et al., 2011); peanut-allergic patients had positive skin tests to sprouts (Jensen et al., 2008). Evidence concerns seedlings and seeds, not extract.
Magnitude: Among 60 birch-pollen-allergic patients’ sera, 73% bound the mung bean allergen Vig r 1 and 32% bound Vig r 6; among 19 patients with reported reactions or positive skin tests to sprouts, 79% and 63% did; no control group, and no population prevalence reported (Guhsl et al., 2014). The European Food Safety Authority (EFSA) also flagged sensitization potential (the capacity to induce allergic antibodies) of mung bean protein for people allergic to soybean, peanut, lupin or birch pollen (EFSA, 2021).
Foodborne Infection From Raw Sprouts
Raw mung bean sprouts have caused repeated Salmonella outbreaks, including 106 German cases in 2011 (Bayer et al., 2014) and US and Canadian outbreaks in 2000-2002 (Mohle-Boetani et al., 2009). Bacteria on seeds can multiply during sprouting (FDA). Evidence concerns raw sprouts, so it is indirect for extract.
Magnitude: Sprout consumption was associated with Salmonella Newport infection with an odds ratio (relative odds of illness in people who consumed sprouts versus those who did not) of 18.4 (95% CI 2.2-150.2), using 50 Newport cases against 45 Enteritidis cases as the comparison group (Bayer et al., 2014).
Speculative 🟨
Thyroid Hormone Synthesis Interference
Vitexin, present in mung bean, impaired thyroid hormone synthesis in rats at the top dose (Gaitan et al., 1995); related compounds inhibit thyroid peroxidase (a hormone-making enzyme) in vitro. Human relevance is unknown.
Trace-Element Exposure
Analysis of four legume species including mung bean found toxic-element levels posing no immediate risk at 50 g/day (Jáudenes-Marrero et al., 2024). Contamination of extracts has not been measured.
Anti-Nutritional Factors
Whole mung bean contains phytic acid, tannins and hemagglutinins (red-cell-clumping proteins), classed as anti-nutrients (compounds that can impair nutrient absorption) (Dahiya et al., 2015, a review). Their content in extracts is unknown.
Risk-Modifying Factors
- Genetic polymorphisms: No gene variants are established as risk modifiers; the main documented modifier, birch-pollen sensitization, is an acquired immune sensitization rather than a defined polymorphism.
- Baseline biomarkers: IgE against Bet v 1 (major birch pollen allergen) occurred in all ten patients reacting to mung bean seedlings (Mittag et al., 2005); Bet v 1 inhibited IgE binding to mung bean allergens (Guhsl et al., 2014).
- Sex: No sex-based differences in mung bean risks have been reported; allergy and outbreak studies did not stratify by sex.
- Allergic conditions: Birch-pollen allergy is linked to reactions to mung bean seedlings (Mittag et al., 2005); some peanut-allergic patients had positive skin tests to sprouts (Jensen et al., 2008).
- Pregnancy & thyroid disease: FDA advises pregnant women to avoid raw sprouts of any kind, including mung bean (FDA). Thyroid disease is a theoretical modifier given vitexin’s antithyroid activity in rats.
- Age: No age-stratified risk data exist for extracts, including at the older end of the target range; sprout outbreaks have involved adult cases (Bayer et al., 2014).
Key Interactions & Contraindications
Prescription medications
- Glucose-lowering drugs (metformin, glipizide, insulin): Monitor (theoretical). Additive glucose lowering could cause hypoglycemia (low blood sugar); the isolate trial found no fasting glucose change in adults not using such drugs (Kohno et al., 2018). Glucose monitoring is the mitigation.
- Blood-pressure drugs (ACE inhibitors, which block ACE, such as lisinopril and enalapril): Monitor (theoretical). Mung bean protein inhibits ACE in vitro, so additive blood-pressure lowering with dizziness is conceivable; no human data exist (Muchimapura et al., 2024).
- Thyroid medication (levothyroxine, methimazole): Monitor (theoretical). Vitexin impaired thyroid hormone synthesis in rats, so thyroid function tests could shift; no human data exist (Gaitan et al., 1995).
Over-the-counter medications
- NSAIDs (nonsteroidal anti-inflammatory drugs such as ibuprofen and naproxen): Low concern (theoretical). Mung bean protein inhibited COX-2 (cyclooxygenase-2, an inflammation enzyme) in vitro, which could add to NSAID effects such as gastric irritation; no interaction has been reported (Muchimapura et al., 2024).
Supplements
- Green tea extract (EGCG, epigallocatechin gallate, a green tea antioxidant): Monitor (theoretical). The one identified seed-coat extract product is combined with 300 mg of EGCG; the consequence, possibly additive adverse effects from EGCG itself, is unstudied in combination (Life Extension product page).
- Iron and zinc supplements: Caution (theoretical). Whole beans contain phytic acid and tannins, classed as anti-nutrients (Dahiya et al., 2015, a review); extract content and any resulting reduction in mineral absorption are unstudied. Separating dosing times is a common precaution.
- Supplements with overlapping glucose- or blood-pressure-lowering effects (berberine, cinnamon, hibiscus): Monitor (theoretical). Additive lowering could cause hypoglycemia or low blood pressure; no studies exist.
Other interventions
- Low-glycemic diets and exercise programs: Monitor (theoretical). Additive glucose lowering, with possible hypoglycemia, is conceivable; no study has combined them with mung bean extract.
Populations who should avoid Mung Bean Extract:
- Individuals with mung bean, soy, peanut or lupin allergy: Avoid. IgE-mediated reactions to mung bean are documented, and EFSA flagged cross-sensitization risk, with anaphylaxis (a severe, life-threatening allergic reaction) a possible consequence (Misra et al., 2011; EFSA, 2021).
- Individuals with birch-pollen allergy and prior reactions to mung bean sprouts or soy foods: Avoid. Bet v 1-type allergens shared with birch pollen were documented (Guhsl et al., 2014).
- Pregnant and breastfeeding individuals: Avoid (theoretical). No safety data exist for the extract; FDA advises pregnant women to avoid raw sprouts (FDA).
Risk Mitigation Strategies
Doses and timings below follow common practice unless cited.
- Cooking sprouts thoroughly: FDA states that cooking significantly reduces sprout-borne illness, mitigating bacterial infection from raw mung bean sprouts (FDA).
- Avoiding raw sprouts in pregnancy: FDA advises pregnant women to avoid raw sprouts of any kind, including mung bean, which prevents sprout-borne bacterial infection (FDA).
- Allergy history review before use: Prior reactions to mung bean, soy, peanut or birch-pollen-related foods signal IgE-mediated reaction risk; the isolate trial excluded participants with food allergies (Kohno et al., 2018).
- Starting at the minimum effective dose: Protein isolate at 3 g/day was judged the minimum dose producing physiological effects in the pre-study, which also tested 1.5 g/day (Kohno et al., 2018); lower exposure limits unknown adverse effects.
- Glucose and blood-pressure monitoring with medication: Checks at 2-4 weeks limit the risk of additive hypoglycemia or low blood pressure alongside glucose- or pressure-lowering drugs.
- Spacing from mineral supplements: Separating mung bean preparations from iron or zinc by several hours limits phytic acid and tannin binding that could reduce mineral absorption (theoretical).
- Limiting use to studied durations: Trials lasted 4-8 weeks, and no long-term safety data exist; periodic reassessment limits exposure to unknown long-term risks.
Therapeutic Protocol
Other parameters without a citation (timing, cycling, titration steps) reflect common practice.
- Seed-coat extract (supplement label): One product provides 240 mg extract (24 mg vitexin, 24 mg isovitexin) with 300 mg EGCG, one capsule daily without food; popularized by Life Extension (product page). No human trial supports this dose.
- Protein isolate (metabolic trials): 3 g/day as chewable tablets twice daily before breakfast and dinner for 8 weeks; 6 g/day tested for 4 weeks. Developed by Fuji Oil (Kohno et al., 2018).
- Protein supplement (strength trial): 18 g/day of mung bean protein in the morning for 8 weeks, from an Arizona State University group (Bartholomae et al., 2019; NCT04076982).
- Functional drink (artery trial): 10 or 15 g/day of mung bean protein before meals for 6 weeks, from a Khon Kaen University group (Muchimapura et al., 2024).
- Whole-food approach: 50-100 g/day of processed foods containing triticale (a wheat-rye hybrid grain) and mung bean for 30 days in type 2 diabetes, from Peking Union Medical College Hospital; no results found (NCT02999867).
- Competing approaches: Coat extract, protein isolate and whole foods have not been compared head to head; protein doses range from 3 to 18 g/day across sources, and none is a default.
- Time of day: Trials used before breakfast and dinner, before meals, or morning; the label states without food. No timing comparison exists.
- Half-life: No human half-life is reported; isovitexin’s rat half-life was about one hour after intravenous dosing (Li et al., 2015).
- Single versus split doses: The label uses one daily capsule; the isolate trial split 3 g into two doses. No comparison exists.
- Genetic polymorphisms: No variants have been studied as influences on dose or protocol.
- Sex differences: Response by sex was not reported in any trial.
- Age: Trials reporting ages enrolled adults aged 20-65 (Kohno et al., 2018) and 45-60 (Muchimapura et al., 2024); no dosing data exist for older adults.
- Baseline biomarkers: The isolate trial reported larger metabolic effects at HOMA-IR of 1.7 or higher (Kohno et al., 2018).
- Pre-existing conditions: Protocols were tested in healthy, overweight, prediabetic-range or vegetarian adults, not in diagnosed disease.
Discontinuation & Cycling
- Duration: Trials lasted 4-8 weeks, and no study evaluated lifelong use, so neither lifelong nor short-term use has a long-term evidence base.
- Withdrawal effects: No withdrawal effects were reported in the isolate or artery-function trials (Kohno et al., 2018; Muchimapura et al., 2024), and none are described for the seed-coat extract.
- Tapering: No tapering protocol exists, and available data give no reason for one.
- Cycling: No study has tested cycling for maintaining efficacy; the product label describes continuous daily use without cycling.
Sourcing and Quality
- Preparation type: Seed-coat extract, protein isolate, sprout-based and whole-food forms differ in composition; trial evidence for isolates does not transfer to coat extract.
- Standardization: The one branded coat extract identified lists 240 mg providing 24 mg each of vitexin and isovitexin, allowing comparison between products (Life Extension product page).
- Third-party testing: ConsumerLab lists no mung bean extract review, so independent potency and contaminant testing is unavailable; third-party seals (e.g., United States Pharmacopeia, a standards body, or NSF International, an independent testing group) are the common indicator.
- Contaminants: Legume crops accumulate trace elements (Jáudenes-Marrero et al., 2024); raw sprouts carry microbial hazards (Mohle-Boetani et al., 2009). Extract contamination data are lacking.
- Allergen content: Protein-containing preparations carry sensitization potential (EFSA, 2021); the protein content of coat extracts is unreported.
- Brands: Life Extension’s Cytokine Suppress is the coat extract identified; GLUCODIA (Fuji Oil) is the isolate studied in trials. Neither has an independent ConsumerLab review.
Practical Considerations
- Time to effect: Metabolic changes appeared at 4 weeks in the isolate pre-study and 8 weeks in the main study (Kohno et al., 2018); artery-function changes at 6 weeks (Muchimapura et al., 2024); no data exist beyond 8 weeks.
- Common pitfalls: Extrapolating protein-isolate trials to coat extract; confusing mung bean (Vigna radiata) with black gram (Vigna mungo), which a registered seed-coat soup trial uses instead of mung bean (NCT07688694); consuming raw sprouts.
- Regulatory status: US extracts are regulated as dietary supplements (FDA); labels state claims are not FDA-evaluated (Life Extension product page). Another mung bean protein isolate received an FDA no-questions letter (GRN 684); EFSA judged mung bean protein safe (EFSA, 2021).
- Cost and accessibility: One coat-extract product lists $21.75 for 30 capsules; cost is low (Life Extension product page).
- Tolerability in trials: The isolate trial reported a well-tolerated dose with no significant group differences in safety parameters (Kohno et al., 2018); the drink trial reported stable general health measures (Muchimapura et al., 2024).
Interaction with Foundational Habits
- Sleep: Direction: none documented. No trial measured sleep outcomes, and no mechanism linking mung bean extract to sleep is established; the product label specifies once-daily use without food, with no sleep-related timing.
- Nutrition: Direction: direct. Whole mung bean has a preparation-dependent glycemic index (11-90 across studies) (Singh et al., 2021, a review); the protein supplies limited sulfur-containing amino acids, and a registered trial tests pairing with rice or wheat (NCT03674723).
- Exercise: Direction: indirect. The strength trial gave protein without an exercise program and found a borderline strength difference (Bartholomae et al., 2019); timing around workouts and effects on training adaptation have not been studied.
- Stress management: Direction: none documented. No study measured cortisol or stress responses; inflammatory markers fell in the artery-function trial but are not stress measures (Muchimapura et al., 2024).
Monitoring Protocol & Defining Success
Baseline testing before starting covers fasting glucose, fasting insulin, triglycerides and liver enzymes, plus a history of legume, peanut or birch-pollen allergy; the isolate trial measured these at baseline (Kohno et al., 2018). Typical monitoring cadence is at 4 weeks, 8 weeks, then every 3-6 months while use continues (common practice; trials ended at 4-8 weeks). Blood pressure and glucose checks matter most alongside blood-pressure or glucose-lowering medication. Samples are drawn fasting and in the morning, matching the trial protocol, so values stay comparable across timepoints and day-to-day variation is limited. Ongoing tests repeat the baseline panel, so changes in glucose, insulin and triglycerides are read against each person’s own starting values.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| Fasting glucose | About 70-99 mg/dL (standard reference range; varies by laboratory) | Safety check: additive lowering with glucose-lowering drugs could cause hypoglycemia | Fasting 8-12 hours; paired with insulin to calculate HOMA-IR; the isolate trial measured it at baseline and follow-up (Kohno et al., 2018) |
| Fasting insulin | About 2-25 µU/mL (standard reference range; varies by laboratory) | Expected-change marker: fell in the isolate trial | Fasting 8-12 hours; paired with glucose to calculate HOMA-IR (Kohno et al., 2018) |
| HOMA-IR | No established target; track change from own baseline | Expected-change marker of insulin resistance | Fasting insulin (µU/mL) x fasting glucose (mg/dL) / 405; the trial classed 1.7 or higher as lower insulin sensitivity (Kohno et al., 2018) |
| Triglycerides | No established target; track change from own baseline | Expected-change marker: shifted in the isolate trial | Fasting 9-12 hours; the trial drew morning samples after an overnight fast (Kohno et al., 2018) |
| ALT | About 7-56 U/L (standard reference range; varies by laboratory) | Expected-change marker: fell in the isolate trial | ALT = alanine aminotransferase, a liver enzyme; the isolate trial measured it with other liver enzymes (Kohno et al., 2018) |
| Blood pressure | No established target; track change from own baseline | Safety check: theoretical additive lowering with blood-pressure drugs | Seated and rested, repeated readings, same time of day |
Qualitative markers include:
- Energy levels and exertional tolerance
- Grip or leg strength
- Digestive comfort (bloating, flatulence)
- Pruritus (itching), oral tingling or urticaria (hives) after dosing
Emerging Research
- Mung bean amino-acid availability (NCT03674723): Toronto study of six healthy men testing usable methionine (an essential amino acid) in cooked mung bean; the registered August 2025 completion has passed, status still reads “active, not recruiting”, no results posted. A positive result refines protein-quality estimates; a null result leaves extract grades unchanged.
- Philippine counterpart (NCT06184984): Six healthy women of reproductive age; listed “not yet recruiting” although the registered December 2025 completion has passed, no results posted. A positive result would add protein-quality data from another population; a null result leaves extract grades unchanged.
- Type 2 diabetes dietary trial (NCT02999867): 180 patients received triticale with mung bean or adzuki bean for 30 days; completed 2017, no results posted. A positive result would support whole-food glycemic effects only; a null result would weaken them.
- Legume allergy cohort (NCT07811141): Lille study of 100 children with legume allergy (peanut excluded), starting 2026 and ending 2034; mung beans are among the legumes listed in its primary outcome. Mung bean allergy cases would strengthen the allergy risk; none would leave its grading unchanged.
- Completed trials with published results: The registered isolate trial (NCT02322294) appears to correspond to the main study of Kohno et al., 2018; NCT04076982 is reported by Bartholomae et al., 2019; both are covered under benefits.
- No registered seed-coat extract trial: ClinicalTrials.gov searches for mung bean, Vigna radiata and vitexin returned none. A controlled trial improving inflammatory or metabolic markers would raise the evidence grade; a null result would weaken the animal-derived case.
- Mechanistic confirmation: AMPK-dependent autophagy (Chen et al., 2026) and HMGB1 lowering (Zhu et al., 2012) lack human confirmation; modest antioxidant activity (Sreerama et al., 2012) could weaken the case.
Conclusion
Mung bean extract covers concentrated preparations of the green gram legume: mainly a seed-coat extract sold as a supplement and an isolated protein studied as a food ingredient. For adults pursuing health and longevity, the evidence base is thin and indirect. Most of the support comes from laboratory and animal work, including longer lifespan in roundworms and altered inflammatory signaling in immune cells, and none of it has been confirmed in human outcome studies. The few human trials tested the protein fraction rather than the seed-coat extract, enrolled small groups for weeks, and produced modest or borderline changes in insulin handling, muscle strength and blood vessel function; no benefit therefore reaches more than low confidence. Documented risks center on allergic reactions in people allergic to birch pollen, peanut or other legumes, and on bacterial contamination of raw sprouts, while other proposed risks rest on animal or laboratory data. Interactions with medicines have not been studied in humans. Commercial interests shape the evidence: the largest metabolic trials came from the protein’s manufacturer, and the best-known seed-coat extract is promoted by the company that sells it. Overall, mung bean extract sits at an early stage, with a plausible biological basis but little direct human proof.